Full Text:
<975>
Summary: 
<416>
Suppl. Mater.: 
CLC number:
On-line Access: 2022-11-15
Received: 2022-05-30
Revision Accepted: 2022-07-28
Crosschecked: 2022-11-16
Cited: 0
Clicked: 1257
High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma
| ||||||||||||||
Xiaoyan YUE, Linlin HUANG, Yang YANG, Yi ZHAO, Donghua HE, Xiaoyan HAN, Gaofeng ZHENG, Yi LI, Enfan ZHANG, Zhen CAI, Xin HUANG, Jingsong HE. High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma[J]. Journal of Zhejiang University Science B, 2022, 23(11): 968-974.
@article{title="High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma",
author="Xiaoyan YUE, Linlin HUANG, Yang YANG, Yi ZHAO, Donghua HE, Xiaoyan HAN, Gaofeng ZHENG, Yi LI, Enfan ZHANG, Zhen CAI, Xin HUANG, Jingsong HE",
journal="Journal of Zhejiang University Science B",
volume="23",
number="11",
pages="968-974",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2200277"
}
%0 Journal Article
%T High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma
%A Xiaoyan YUE
%A Linlin HUANG
%A Yang YANG
%A Yi ZHAO
%A Donghua HE
%A Xiaoyan HAN
%A Gaofeng ZHENG
%A Yi LI
%A Enfan ZHANG
%A Zhen CAI
%A Xin HUANG
%A Jingsong HE
%J Journal of Zhejiang University SCIENCE B
%V 23
%N 11
%P 968-974
%@ 1673-1581
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2200277
TY - JOUR
T1 - High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma
A1 - Xiaoyan YUE
A1 - Linlin HUANG
A1 - Yang YANG
A1 - Yi ZHAO
A1 - Donghua HE
A1 - Xiaoyan HAN
A1 - Gaofeng ZHENG
A1 - Yi LI
A1 - Enfan ZHANG
A1 - Zhen CAI
A1 - Xin HUANG
A1 - Jingsong HE
J0 - Journal of Zhejiang University Science B
VL - 23
IS - 11
SP - 968
EP - 974
%@ 1673-1581
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2200277
Abstract: multiple myeloma (MM) is a common malignant hematological tumor in adults, which is characterized by clonal malignant proliferation of plasma cells in the bone marrow and secretion of a large number of abnormal monoclonal immunoglobulins (M protein), leading to bone destruction, hypercalcemia, anemia, and renal insufficiency (Alexandrakis et al., 2015; Yang et al., 2018). Since a large number of new drugs, represented by proteasome inhibitors and immunomodulators, have been successfully used to treat MM, treatment efficacy and survival of patients have been significantly improved. However, due to the high heterogeneity of this disease, patients have responded differently to treatments with these new drugs (Palumbo and Anderson, 2011; Wang et al., 2016; Huang et al., 2020). Growth and survival of MM cells depend on the bone marrow microenvironment, especially numerous inflammatory cytokines secreted by myeloma cells and bone marrow stromal cells, such as vascular endothelial growth factor (VEGF), interleukin (IL)-6, transforming growth factor-β (TGF-β), and IL-10. These cytokines can promote the growth of myeloma cells, induce angiogenesis, and inhibit antitumor immunity, and are often linked to patient prognOSis (Kumar et al., 2017). In this era of new drugs, the prognOStic values of the serum levels of these cytokines in MM need further evaluation.
[1]AlexandrakisMG,GoulidakiN,PappaCA,et al.,2015.Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma.Pathol Oncol Res,21(4):929-934.
[2]FayadL,KeatingMJ,ReubenJM,et al.,2001.Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.Blood,97(1):256-263.
[3]GuptaM,HanJJ,StensonM,et al.,2012.Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation.Blood,119(12):2844-2853.
[4]HeJS,HeDH,HanXY,et al.,2020.Bortezomib-based regimens for newly diagnosed multiple myeloma in China: a report of 12-year real-world data.Front Pharmacol,11:561601.
[5]HeJS,YueXY,HeDH,et al.,2021.Multiple extramedullary-bone related and/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma.Front Oncol,11:668099.
[6]HuangH,WuHW,HuYX,et al.,2020.Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.J Zhejiang Univ-Sci B (Biomed & Biotechnol), 2020,21(1):29-41.
[7]KumarSK,RajkumarV,KyleRA,et al.,2017.Multiple myeloma.Nat Rev Dis Primers,3:17046.
[8]MinnieSA,KunsRD,GartlanKH,et al.,2018.Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.Blood,132(16):1675-1688.
[9]MusolinoC,AllegraA,InnaoV,et al.,2017.Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma.Mediators Inflamm,2017:1852517.
[10]Načinović-DuletićA,ŠtifterS,DvornikŠ,et al.,2008.Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma.Int J Lab Hematol,30(3):230-239.
[11]PalumboA,AndersonK,2011.Multiple myeloma.N Engl J Med,364(11):1046-1060.
[12]RajkumarSV,DimopoulosMA,PalumboA,et al.,2014.International myeloma working group updated criteria for the diagnosis of multiple myeloma.Lancet Oncol,15(12):e538-e548.
[13]RyuD,KimSJ,HongY,et al.,2020.Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion.Clin Cancer Res,26(4):935-944.
[14]ShekarrizR,JanbabaeiG,KenariSA,2018.Prognostic value of IL-10 and its relationship with disease stage in Iranian patients with multiple myeloma.Asian Pac J Cancer Prev,19(1):27-32.
[15]WangH,WangL,ChiPD,et al.,2016.High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.Br J Cancer,114(4):463-468.
[16]YangRN,ChangQ,MengXC,et al.,2018.Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis.J Cancer,9(18):3295-3302.
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>